FOLH1 and breast cancer: Another study, published by Medina-Ornelas et al., compared 18FDG and 68Ga-PSMA PET/CT in 21 patients with breast cancer, reporting lower detection rates for 68Ga in patients with hormones-positive receptors and a comparable detection rate in triple-negative patients, supporting the possible role of 68Ga-PSMA PET/CT in the risk stratification and identification of the aggressiveness of the disease [62].